title: [Consensus document on the treatment of dyslipidemia in diabetes].
abstract: People with type 2 diabetes mellitus have a 2 to 4 times higher risk of developing cardiovascular diseases when compared to general population of similar age and sex. This risk remains after adjustment of other traditional cardiovascular risk factors. The dyslipidemia associated with type 2 diabetes mellitus is present in up to 60% of people with diabetes and contributes greatly to increased cardiovascular, morbidity and mortality risk in these patients. Diabetic dyslipidemia is a disorder of lipid metabolism characterized by an excess of triglycerides, a decrease in HDL-cholesterol and altered lipoprotein composition, consisting mainly in an excess of small, dense LDL particles. Multiple clinical trials have demonstrated the benefits of drug treatment of dyslipidemia (mainly statins) to prevent cardiovascular events and mortality in people with diabetes, both in primary and secondary prevention. This consensus document, developed by general practitioners, members of the Diabetes Group of the Spanish Society of Primary Care Physicians (SEMERGEN), aims to assist in the management of patients with diabetes and dyslipidemia in accordance with the most recent recommendations.
authors.affiliation: Medicina Familiar y Comunitaria, Unidad de Gestión Clínica Puerta Blanca, Distrito Sanitario Málaga-Guadalhorce, Málaga, España. Electronic address: cpuertablanca@hotmail.com.
authors.forename: A
authors.initials: A
authors.lastname: Hormigo-Pozo
authors.affiliation: Medicina Familiar y Comunitaria, Centro de Salud Ciudad Jardín, Distrito Sanitario Málaga-Guadalhorce, Málaga, España.
authors.forename: J
authors.initials: J
authors.lastname: Mancera-Romero
authors.affiliation: Medicina Familiar y Comunitaria, Centro de Salud Dr. Castroviejo, Dirección Asistencial Norte, Madrid, España.
authors.forename: M P
authors.initials: MP
authors.lastname: Perez-Unanua
authors.affiliation: Medicina Familiar y Comunitaria, Centro de Salud La Eria, Oviedo, España.
authors.forename: M
authors.initials: M
authors.lastname: Alonso-Fernandez
authors.affiliation: Medicina Familiar y Comunitaria, Área Básica de Salud Martorell, Barcelona, España.
authors.forename: F
authors.initials: F
authors.lastname: Lopez-Simarro
authors.affiliation: Medicina Familiar y Comunitaria, Centro de Salud Burgos Rural, Burgos, España.
authors.forename: J J
authors.initials: JJ
authors.lastname: Mediavilla-Bravo
mesh_terms: D003131:Combined Modality Therapy; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000503:physiopathology; D050171:Dyslipidemias / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology / Q000628:therapy*; D015438:Health Behavior; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D011320:Primary Health Care / Q000379:methods; D012307:Risk Factors
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents
keywords: Consenso; Consensus; Diabetes mellitus tipo 2; Diabetes mellitus type 2; Dislipidemia; Dyslipidemia; Factores de riesgo; Risk factors